Tempest Therapeutics, Inc. (TPST)
NASDAQ · Manufacturing · Pharmaceutical preparations
$0.8225−$0.0275 (−3.24%) on the dayAs of the close; data may be delayed.
TPST price, last 12 months
Key stats
- Previous close
- $0.8500
- Open
- $0.8515
- Day range
- $0.8150 – $0.9007
- 52-week range
- $0.7432 – $6.12
- Volume
- 275.9K
- Avg volume (20 days)
- 7.7M
- Market cap
- $13.7M
Performance
1W−15.0%
1M−23.8%
3M−23.8%
6M−50.5%
YTD−42.7%
1Y−82.1%
vs S&P 500, 1Y−98.9 pts
Technicals and fundamentals
About Tempest Therapeutics, Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $13.7M